✦ LIBER ✦

Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease

✍ Scribed by Rodrigues, Tiago Martins; Jerónimo-Santos, André; Outeiro, Tiago Fleming; Sebastião, Ana Maria; Diógenes, Maria José

Book ID: 125386871
Publisher: Springer International Publishing AG
Year: 2014
Tongue: English
Weight: 544 KB
Volume: 31
Category: Article
ISSN: 1170-229X
DOI: 10.1007/s40266-014-0160-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Challenges to the development of disease

Challenges to the development of disease-modifying therapies in Parkinson’s disease

✍ A. H. V. Schapira 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

Development of effective therapy for Alz

Development of effective therapy for Alzheimer's disease based on neurotrophic factors

✍ Franz Hefti 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 227 KB

[Progress in Brain Research] Recent Adva

[Progress in Brain Research] Recent Advances in Parkinson’S Disease - Translational and Clinical Research Volume 184 || Neurotrophic factor therapy for Parkinson’s disease

✍ Rangasamy, Suresh Babu 📂 Article 📅 2010 🏛 Elsevier 🌐 English ⚖ 635 KB

Preclinical and clinical challenges in t

Preclinical and clinical challenges in the development of disease-modifying therapies for Alzheimer's disease

✍ Carol A Scorer 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 130 KB

3.413 Development of a Dutch evidence ba

3.413 Development of a Dutch evidence based guideline for occupational therapy in Parkinson's disease

✍ I. Sturkenboom; B.R. Bloem; M. Munneke 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 52 KB

In vivo gene delivery of glial cell line

In vivo gene delivery of glial cell line–derived neurotrophic factor for Parkinson's disease

✍ Jeffrey H. Kordower 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 564 KB

Parkinson's disease (PD) is a progressive neurodegenerative disorder that affects approximately 1,000,000 Americans. The cause of the disease remains unknown. The histopathological hallmarks of the disease are dopaminergic striatal insufficiency secondary to a loss of dopaminergic neurons in the sub